Maze generated $20.0 million of revenue in the six months ended June 30, after recording none in the comparable period. That is roughly $2.70 of operating cash outflow for every dollar of revenue, a useful scale comparison for a biotech still funding its pipeline.
The new revenue did not turn the business profitable. Operating loss widened to $48.0 million from $36.5 million, while net loss reached $44.7 million from $33.7 million. The diluted share count rose 34.7% to 59.0 million, so the nearly unchanged diluted loss per share, negative $0.76 versus negative $0.77, reflects more shares absorbing the loss.
Maze says the larger operating loss came mainly from personnel, clinical development, and discovery spending. Research and development expense rose 24.3% to $34.9 million, and stock-based compensation, a non-cash expense, rose to $9.2 million from $3.2 million.
The company’s explanation points to a business spending more as its programs advance, not one cutting costs to match its new revenue. In its six-month comparison, Maze wrote:
"The increase of $13.4 million between the comparative six month periods was primarily due to an increase of $7.9 million in personnel-related costs due to an increase in headcount and higher non-cash stock-based compensation expense, an increase of $5.7 million related to progression of our clinical development of the MZE829 program and an increase of $0.9 million related to our discovery research and other programs, partially offset by a $0.5 million decrease related to the MZE782 program primarily due to higher costs incurred in 2025 for the Phase 1 clinical trial in healthy adult volunteers that completed in 2025 and a $0.6 million decrease in lab supplies and other costs."
Maze Therapeutics, 10-Q, Aug. 11, 2026
In plain English, headcount and pipeline work accounted for the disclosed increase, with the completed MZE782 trial providing only a partial offset. The filing does not identify the source of the $20.0 million in revenue.
Cash use improved slightly, falling to $54.2 million from $59.6 million, but the balance still declined 23.4% to $202.6 million. Capex dropped 71.1% to $200,000, which leaves research and development, rather than equipment spending, as the larger operating claim on cash.
Maze described the cash flow in these terms:
"The net cash used in operating activities for the six months ended June 30, 2026 was primarily due to our net loss of $68.9 million combined with a net change in our operating assets and liabilities of $4.6 million, offset by $19.3 million in non-cash charges such as depreciation, stock-based compensation, lease expense and amortization of debt discount and debt issuance costs."
Maze Therapeutics, 10-Q, Aug. 11, 2026
That bridge matters because the reported loss includes $19.3 million of non-cash charges, while the cash account reflects the actual operating outflow. Maze also says it expects “significant and increasing losses” for the foreseeable future as research and development continues.
The capital structure adds another piece to the runway question. In February, Maze entered a senior secured term-loan facility with Hercules Capital and other lenders for up to $200.0 million. The facility is disclosed, not a promise that the full amount has been drawn, but it gives the balance sheet a financing relationship alongside the $202.6 million cash balance.
After the period, Neurocrine notified Maze that it intends to terminate its license agreement effective November 2026. That leaves the next report with a specific comparison to make: operating cash flow against the latest six-month outflow of $54.2 million, alongside $20.0 million of revenue.
Source: Maze Therapeutics’ Form 10-Q filed Aug. 11, 2026, for the six months ended June 30, 2026.